

Ofer Mandelboim

Academic achievements:

1991; MSc Degree, Weizmann Institute of Science, Rehovot, Israel

1996; PhD Degree, Weizmann Institute of Science, Rehovot, Israel

1995-1999; Post-doctoral research fellow with Prof. Jack L Strominger, Department of Molecular and Cellular Biology, Harvard University, USA

Working experience:

1999-2004; Senior Lecturer, The Lautenberg Center for General and Tumor Immunology, The Hebrew University, Hadassah Medical School

2005-2007; Associate professor of Molecular Immunology, The Lautenberg Center for General and Tumor Immunology, The Hebrew University, Hadassah Medical School

2007-present; Full Professor of Molecular Immunology, The Lautenberg Center for General and Tumor Immunology, The Hebrew University, Hadassah Medical School.

Principal investigator in ongoing projects:

- principal investigator of total of **33 research grants**

2010-2017-ICRF professorship grant. Learning from viruses: MicroRNAs controlling tumor cell attack by NK cells. \$50000/year for 7 years, \$350000 in total.

2011-2015-The Israel Science Foundation (ISF). Cellular and viral miRNA controlling innate immune response. \$70000/year for 4 years \$280000 in total.

2012-2013- The Israel Science Foundation and JDRF. NK cells and diabetes development. 250,000 shekels for one year.

2013-2018-ERC advanced grant-ERC. Recognition of bacteria by NK cells. 2,500000 Euro total.

2014-2017-GIF Regulation of HLA-G expression. 180000 Euro in total.

Research achievements (selected):

1995-1996 The Rothschild Fellowship for post-doctoral research studies.

1995-1996 The Fulbright Fellowship for post-doctoral research studies.

1995-1997 The EMBO Long Term Fellowship for postdoctoral research studies.

1997-2000 A post-doctoral research fellowship from the Cancer Research Fund of the Damon Runyon -Walter Winchell Foundation.

2000-2001 Award by the L. Naftali Science Foundation award for Biology and Medicine, \$20,000 for research.

2000-2005 Award by the Israel Cancer Research Fund (ICRF) with the Research Career Development Award (RCDA), \$ 30,000/year for 5 years.

2001 Award by the Hebrew University with the Ben-Porat Award for the best young investigator in the university.

2002 Award by Teva with the Teva Founder Award, 65,000 shekels for research.

2004 Award by the Juludan Prize for basic studies in medical research from Technion, Haifa.

2007 Award with a lectureship award in the amount of \$2,500 from the Institute of Human Development, Child and Youth Health (IHDCYH)

2009 Teva award for immunological research.

Relevant publications:

- 124 original articles and 15 reviews

- 1. Mandelboim O**, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, Davis DM, Strominger JL, Yewdell JW, and Porgador A. 2001. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human natural killer cells. *Nature*. 409: 1055-1060.
- 2.** Stern-Ginossar N, Elefant N, Zimmermann A, Wolf D, Saleh N, Biton M, Horwitz E, Prokocimer Z, Prichard M, Gabriele Hahn, Goldman-Wohl D, Greenfield C, Yagel S, Hengel H, Altuvia Y, Margalit H, **Mandelboim O**. 2007. Host immune system gene targeting by a viral miRNA. *Science*. 317: 376-381.
- 3.** Stern-Ginossar N, Gur C, Biton M, Horwitz E, Elboim M, Stanietskey N, Mandelboim M, **Mandelboim O**. 2008. Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. *Nature Immunology*, 9: 1065-1073.
- 4.** Nachmani D, Lankry D, Wolf DG, **Mandelboim O**. 2010. The human cytomegalovirus microRNA miR-UL112 acts synergistically with a cellular microRNA to escape immune elimination. *Nature Immunol*. 11(9):806-13.
- 5.** Elboim M, Grodzovski I, Djan E, Wolf DG, **Mandelboim O**. HSV-2 specifically down regulates HLA-C expression to render HSV-2-infected DCs susceptible to NK cell killing. *PLoS Pathog*. 2013 Mar;9(3):e1003226.

Patents:

NK cell activating receptors and their therapeutic and diagnostic uses (PCT/IL01/00664)